VOLUME 37 1990

SUBJECT INDEX

Acetylcholine, 155, 213, 597
Acetylcholinesterase, 439
α_1-Acid glycoprotein, AGP, 485
Acquisition, 405
Active avoidance, 295
Adenosine, 107
Adenosine analogs, 747
Adenosine A_1 receptor, 747
Adenosine A_{2a} receptor, 747
Adenosine receptors, 107
Adenylate cyclase, 417
Adrenal medulla, 135
Adrenalectomy, 399, 703
Adrenodemedullation, 399
Affect, 425
Affective disorders, 213
Aggression, 101, 493
Aggressive behavior, 433
Agonist/antagonists, 193
Agonist sensitivity, 627
Alcohol, 17, 29, 359
Alpha$_2$-receptors, 675
Alprazolam, 177, 365
(−)Alprenolol, 83
Alzheimer's disease, 405, 799
D-Amino acids, 593
Amnesia, 47, 53, 295
Amphetamine, 259, 303, 417, 451
d-Amphetamine, 349, 493
Amygdala, 439
Analeptic, 375
Analgesia, 123, 193, 497, 661, 713
Angiotensin I, 831
Angiotensin II, 831
Angiotensin converting enzyme, 831
Anisomycin, 295
Anorexia, 201
Antagonism, 505
Anticholinesterase, 267
Antidepressant, 167, 247
Antipanic agents, 167, 177
Antipsychotic, 235
Anxiety, 167, 177
Anxiolytic, 235, 335
Apomorphine, 89, 231, 253, 451, 471, 755
Aprophen, 117
Arecoline, 213
Asymmetric dissociation, 47
Atropine, 117
Atypical neuroleptic obesity, 227
Autogrooming, 63
Autoimmune disease, 527
Aversion, 311, 689
Aversive behavior, 785
Aversive response, 779
Avoidance, 843
Avoidance acquisition, 655
Avoidance behavior, 571

Bar press, 339
Bar pressing, 187
Barbiturate, 343
Baroreceptor reflex, 821
Barrel rotation, 523
Behavior, 11, 71, 135, 289, 349, 627, 649, 717, 831
Behavior genetics, 795
Behavioral indices, 567
Benzodiazepine, 587
Benzodiazepine receptors, 365
Bestatin, 779
Beta receptor subsensitivity, 567
Beta-1 vs. beta-2 specificity, 567
Bicuculline, 667
Biological marker, 485
Bipolar affective illness, 417
Blood and brain ethanol, 577
Blood pressure, 325
BMY 7378, 283, 335
Body composition, 393
Body temperature, 773
Body weight, 17, 379, 393
Bombesin, 689
Brain catecholamines, 639
Brain monoamines, 259
Brain regions, 461
Bromopride, 571
α-Bungarotoxin binding sites, 239
Buprenorphine, 193, 247
Bupropion, 167, 247
Burying behavior, 77
Buspirone, 235, 335, 451
Butorphanol, 193, 511
[^{35}S] *t*-Butylbicyclophosphorothionate binding, 433

Caffeine, 349
Calcium, 457
Calcium channels, 253
Cannabidiol, 299
Cannabinol, 299
Capsaicinized chow, 649
Captopril, 779, 831
Carbamazepine, 551
Carbohydrate, 207, 735
Carbohydrate intake, 461
Carboxyhemoglobin, 17, 29
Castration, 471
Cat, 1, 283
Catecholamines, 259
CCK-A receptor, 523
Ceruletide, 523
CGS 9896, 235
Chemical stimulation, 411
Chlordiazepoxide, 101, 177, 235, 311
Chlorpromazine, 235
Choline deprivation, 799
Cholinergic, 117, 213, 375
Cholinergic function, 811
Cholinesterase, 161
Chow, 649
Chronic cannulae, 411
Chronic stress, 675
Chronic treatment, 567
Cigarette yield, 17, 29
Circadian rhythms, 239
Circling, 387
Classical conditioning, 231
Clonidine, 167, 821
CNS depression, 795
Cocaine, 161, 339, 349, 359, 371, 375, 551, 643, 693, 707, 761, 773, 795
Cocaine N-demethylase, 161
Coffee, 17, 29
Cognitive tasks, 561
Cold tolerance, 107
Colliculus superior, deeper layers, 1
Conditioned avoidance, 639
Conditioned place preference, 425, 633, 383
Conditioned taste aversion, 59, 497, 693
Conflict behavior, 167, 177
ω-Conotoxin, 253
Consistency, 697
Controllability, 613
Convulsions, 577
Copulation, 471
Cortex, 135
Cortical stroke, 679
Corticosterone, 613
pCPA, 83, 283
Cyclohexylamine, 445
Cyclophosphamide, 527
Cytisine, 113

D1 receptor, 289, 317, 627
D2 receptor, 227, 289, 317, 371, 627
DA receptors (presynaptic), 675
Day-old chicks, 729
Delay of reinforcement, 643
Delta-9-tetrahydrocannabinol, 349
Demeclocycline, 417
Dependence, 59, 343
Depression, 213
Desipramine, 167, 277
Development, 129, 161
Developmental trends, 811
Diazepam, 77, 451, 505
Diet selection, 207, 461
Differential reinforcement of response duration schedule, 607
DiMe-C7, 329, 839
Discrimination, 843
Diurnal cycle, 201
DMI, 675
Dog, 607
DOI, 825
DOM, 769
Dominance rank, 493
L-Dopa, 259
DOPAC, 571
Dopamine, 89, 113, 135, 149, 227, 277, 289, 317, 329, 465, 471, 539, 607, 627, 639
Dopamine receptors, 387
Dorsal noradrenergic bundle, 597
Doxepin, 247
DPDPE, 193
Drinking, 531
Drinking behavior, 527
Drug discrimination, 289, 511, 623, 769
Drug interactions, 349
Drug withdrawal, 785
Drugs of abuse, 425, 633
Dystonia, 129

Ear-scratch, 95
EEG, 761
EEG arousal, 375
Effect-addition, 349
Efficiency of food utilization, 393
Electrical brain stimulation, 311
Emesis, 283
Endogenous opioids, 193
Endogenous serotonin uptake modualtor, 485
Endogenous state dependency, 47
β-Endorphin, 47, 661
Enhancement of retrieval, 47
[Leu]Enkephalin, 655
Enkephalin metabolites, 655
Enkephalins, 593
Estrous cycle phase differences, 77
Ethanol, 205, 359, 379, 747
Ethanol intake, 633
Ethanol intoxication, 577
Ether, 399
Ethylketocyclazocine, 193, 713
Excitatory amino acids, 843
Excitotoxin lesions, 755
Experimental model, 811
Exploratory activity, 743
Exploratory behavior, 445

F344 rats, 795
FAD-monooxygenase, 161
False cholinergic transmitter, 799
False precursor (NADe), 811
False transmitter, 811
Fasciculin, 439
Fat, 207, 317
Feeding, 201, 207, 317, 497, 531
Feeding behavior, 735
Fenfluramine, 219, 623
Fentanyl, 193
FG 7142, 311
Fixed interval schedule, 339
Flesinoxan, 335
Flumazenil, 505
cis-Flupenthixol, 387
Food intake, 207, 393, 461
Foot-shock, 303
Formalin test, 713
β-Funaltrexamine, 713

GABA, 329
$GABA_A$ receptor, 343
Ganglioside, 679
Gender differences, 77
Genetic, 831
Genetic mouse lines, 593
Gepirone, 451
Glucose and saccharin, 551
Glucose incorporation, 393
Glycemia, 399
Glycerol renal failure, 583
GM1, 679
Grooming, 689

Haloperidol, 451, 607
Hamster, 383
Heart rate, 325
Hedonics, 317
Hepatotoxicity, 161
Hippocampus, 149, 375
5-HIAA, 461
Holeboard, 273
HPLC of cholinergic compounds, 799
5-HT, 461
$5\text{-}HT_{1A}$, 769
$5\text{-}HT_2$, 769
$5\text{-}HT_1$ agonist, 83
$5\text{-}HT_{1A}$ agonists, 335
$5\text{-}HT_{1A}$-receptor, 95
$5\text{-}HT_{1B}$-receptor, 95
$5\text{-}HT_2$-receptor, 95
5-HT turnover, 461
6-Hydroxydopamine, 231, 329, 755
Human performance, 561
Human subjects, 511
HVA, 571
Hydromorphone, 511
Hyperbaric environment, 577
Hyperthermia, 761
Hypobaric hypoxia, 53
Hypothalamus, 299
Hypothermia, 343, 649
Hypothyroidism, 627
Hypovolemia, 821

Imipramine, 567
Immunoassay, 485
Indorenate, 83
Inescapable shock, 539
Inhibitor, 831
Interaction, 95, 405, 761
Intermediate memory, 729
Intracerebroventricular, 193, 329, 747
Intracranial cannula, 411
Intracranial injection, 743
Intracranial self-stimulation, 187
Intrathecal injection, 779
Intravenous, 551
Ipsapirone, 335
Ischemia, 679

Kainic acid, 71, 755
Ketamine, 667
Ketanserin, 129
Ketotifen analogues, 785
Kindling, 685, 761
Kynurenic acid, 843
Kynurenine, 71

Lab-field comparison, 697
Lateral hypothalamic area, 393
Lateral hypothalamus, 227
LD_{50}, 205
Learning, 679
Learning and memory, 41
Lethality, 267
D-Leucine, 593
LHRH, 639
Ligand binding, 717
Limbic system, 149
Lithium, 417
Locomotion, 113
Locomotor activity, 89, 135, 149, 239, 259, 303, 329, 339, 743, 795
Low doses, 607
Luteinizing hormone, 299

Macronutrient, 207, 735
Male and female rats, 693
Marijuana, 561
Marmoset, 717
Masculine sexual behavior, 83
MDMA, 633
Mecamylamine, 405
Medial hypothalamus, 735
Medial preoptic area, 471
Median raphe nucleus, 329
Memory, 155, 295, 439, 597, 679
Memory consolidation, 729
Memory files, 47
Memory modulation, 655
Meperidine, 193
Mesencephalic locomotor region, 311
Mesolimbic dopamine system, 303
Mesulergine, 283
Metabolic control, 393
Metergoline, 283
Methadone, 247
Methemoglobin, 457
Methylenedioxymethamphetamine, 633
Mianserin, 167
Mice, 101, 161, 273, 505
Microdialysis, 227
Microinfusion, 411
Microinjection, 411
Midazolam, 335
Minocycline, 417
MK-329, 523
MK-801, 41, 101
Morphine, 59, 207, 303, 349, 383, 425, 505, 531, 689, 713
Morphine analgesia, 703
Morphine content, 703
Motor behavior, 1
Motor coordination, 83
Motor incoordination, 747
Mouse, 655, 717, 785
Mrl lpr/lpr mice, 527
Mu, kappa and delta opioid receptors, 193
Multiple cannulae, 411
Muscarinic, 213, 811
Muscarinic receptor binding, 439
Muscimol, 329

Nalbuphine, 193, 511
Nalmefene, 497
Naloxone, 383, 425, 511, 531, 593
Naltrexone, 425, 497
NBR rats, 795
α-Neoendorphin, 661
Neural transplants, 135
Neurokinin A, 779
Neuroleptics, 465, 607
Neuronal plasticity, 685
Nicergoline, 53
Nicotine, 11, 59, 113, 239, 743
Nicotine tolerance, 743
Nicotinic receptors, 239
Nimodipine, 457
Nipple attachment, 219
NMDA, 685
Nonsmokers, 11
Noradrenaline, 539, 597, 729
Norepinephrine, 299, 639
Norethisterone, 477
19-Nor steroids, 477
Nose poke, 339
Novelty, 89
Nucleus accumbens, 113, 149, 303, 329, 743
Nucleus basalis magnocellularis, 597
Nucleus subcoeruleus, 187
Nucleus tractus solitarius, 821

8-OH-DPAT, 769
5-OMe DMT, 769
Ontogenesis, 667
Open-field behavior, 213

Operant behavior, 117, 465
Opioid, 207, 247, 425, 511, 593
Opioid antagonist, 497
Opioid binding, 505
Oxytocin, 63, 253

Pain, 689
Palatability, 451
Panic disorder, 167, 177
Paraventricular nucleus, 201, 735
Parietal, 679
Passive avoidance, 405
Pavlovian conditioning, 205
Penile erection, 253
Pentazocine, 193
Performance, 11, 643
Periaqeductal gray, 311
Perinatal treatment, 571
Perinatal undernutrition, 675
Perseveration, 679
Phenobarbital, 177
D-Phenylalanine, 593
Phenylpropanolamine, 201
Phospholipids, 799
Phosphoramidon, 779
Physiological effects, 561
Physostigmine, 117, 155, 187
Picrotoxin, 667
Pigeons, 247, 349
Pimozide, 465
(−)Pindolol, 83
Pituitary, 299
Pizotifen, 461
Place-preference, 89, 383, 689
Plasma catecholamines, 359
Plasma cotinine, 17, 29
Plasma free fatty acids, 393
Plasma glucose, 393
Plasma insulin, 393
Plasma nicotine, 17, 29
Plasma THC levels, 561
Porsolt's swim test, 273
Positive affect, 633
Positive reinforcement, 317, 425
Postsynaptic receptors, 283
Power-spectra (FFT), 761
Prednisolone, 703
Prefrontal cortex, 685
Prenatal, 371
Preparedness, 613
Pressure reversal, 577
Presynaptic DA2 receptors, 607
Primary polydipsia, 831
Profadol, 193
Progesterone, 433
Progestin metabolism, 477
Progestins, 477
Progressive degenerative dementia, 811
Prolactin, 571
Propranolol, 283
Protein, 207, 735
Protein intake, 461
Psychomotor stimulant, 339
Psychomotor tasks, 561
Puffing topography, 29
Punished responding, 335
Putrescine, 445
Pyridostigmine, 267

Quantitative autoradiography, 433
Quinpirole, 289, 387
Quipazine, 129, 219

Radioligand binding, 557
Rat, 41, 71, 117, 123, 187, 227, 235, 253, 289, 311, 379, 471, 531, 539, 551, 577, 597, 623, 627, 643, 667, 689, 717, 761, 785, 843
Rat brain cortex, 445
Rat brain membranes, 365
Rat strains, 339
Reactivity, 697
Receptor binding, 365, 497
Receptors, 213
Reference memory, 587
Regression, 1
Residual effects, 561
Restraint stress, 193
Retention, 405
Reversal learning, 155
Reward, 317, 425, 465, 685
Ring-methyl amphetamine analogs, 835
Ro15-1788, 177
Rotation behavior, 231, 755
RU 24969, 335
Runway, 531

Schedule-controlled behavior, 339
Scopolamine, 117, 405, 587, 597
Scratching, 689
Seizure, 343, 583, 667, 761
Self-administration, 551, 707
Self-stimulation reward, 277
Sensitization, 303, 707, 761
Sensory, perceptual, and cognitive behaviors, 811
Serial discrimination, 155
Serotonergic anxiolytics, 77
Serotonin, 129, 219, 539, 623, 735, 769, 825
Serotonin receptors, 283
Serotonin syndrome, 83
Serum estradiol, 325
Serum testosterone, 325
Sex differences, 325, 539
Sexual behavior, 63, 477, 825
Sham feeding, 317
Sigma receptor, 557
Single tube procedure, 693
SKF 38393, 289, 387
SM 3997, 335
Smokers, 11
Smoking history, 17, 29
SMS 201-995, 523
Social interactions, 63
Sodium nitrite, 457
Soman, 267
Somatostatin, 523
Spatial learning, 405, 587
Spinalization, 505
Spontaneously hypertensive rats, 773
Squirrel monkeys, 335
Steroids, 123
Stimulus properties, 835
Stimulus properties of drugs, 623
Stress, 213, 273, 359, 399, 661, 773
Stressor, 613
Stress-related hormones, 729
Stress response, 485
Striatum, 135, 371, 755
Stroke, 679
Stumptail macaques, 493
Subjective effects, 561
Substance P, 329, 779, 839
Substantia nigra, 135
Substantia nigra lesions, 231
Sulpiride, 227, 607
Supersensitivity, 623, 755
Suprachiasmatic nucleus, 735
Switch-off test, 311

Tail-flick, 661
Tail-flick assay, 193
Taste, 317
Taste aversion, 551
Taste aversion learning, 379
Taste reactivity, 451
Tegretol, 551
Temporal regulation, 607
Testosterone, 299, 471
Tetrahydrocannabinol, 299
Theophylline neurotoxicity, 583
Thermogenesis, 107
Thiocyanate, 17, 29
Three-session paradigm, 47
Thyroid hormones, 627
Tiflucarbine, 769
Timeout from avoidance, 235
Tolerance, 205, 239, 343
Toxicity, 497
Trazodone, 167
Tremor, 129
Triazolobenzodiazepines, 365
Tryptophan, 273
Two-tube choice procedure, 693
Tyrosine, 259

U50,488, 713
U50,488H, 193, 531
Urinary catecholamines and cortisol, 697

Vasopressin, 821
Ventral tegmental area, 329, 839
Verapamil, 457
Vigilance, 643
Viloxazine, 567
Vinburnine, 53
Vincamine, 53
Voles, 63
Voluntary consumption, 359

Water maze acquisition, 41
Water reinforcement, 465
Weakly reinforced training, 729
Weanling rats, 219
Wet dog shakes, 825
White-dark preference, 445
Withdrawal, 59
Working memory, 587
WY 47,846, 335

Xylamidine, 219

Yawning, 253

R(+)- and S(−)-Zacopride, 717

AUTHOR INDEX

Aaltonen, M., 405
Abbott, F. V., 713
Ader, R., 527
Agmo, A., 83
Ahlenius, S., 843
Ali, S. F., 371
Allen, J. T., 497
Angst, M. J., 311
Anisman, H., 613
Arezo, S., 59
Argiolas, A., 253
Arnold, F. J., 485
Asencio, M., 551
Awad, A., 393

Baker, M. L., 343
Baptista, T., 227
Bardo, M. T., 89
Barnes, J. M., 717, 839
Barnes, N. M., 717, 785, 839
Barrett, J. E., 335
Bartke, A., 299
Bateman, S. T., 219
Battaglia, G., 557
Bättig, K., 743
Becker, C. A., 167
Bellinger, L. L., 393
Belmaker, R. H., 417
Beninger, R. J, 387
Benloucif, S., 295
Bennett, E. L., 295
Berge, O.-G., 577
Bernardis, L. L., 393
Berridge, K. C., 451
Berz, S., 743
Beyer, C., 123
Bigelow, G. E., 511
Bilsky, E. J., 425, 633
Boer, G., 539
Booth, R. A., 799, 811
Bridges, R. B., 17, 29
Brostrom, P. A., 497
Brown, J. W., 259
Bruhwyler, J., 607
Bydlowski, C. R., 639
Byrd, L. D., 493

Caba, M., 123
Calcagnetti, D. J., 193
Cameron, D. L, 627
Cannon, D. S., 379
Canonaco, M., 433
Carino, M. A., 375
Carroll, M. E., 551
Carter, C. S., 63
Chleide, E., 607
Cleary, J., 247
Clissold, D. B., 155
Cohen, N., 527
Combs, J. G., 17, 29
Commissaris, R. L., 167, 177
Cone, E. J., 561
Cools, A. R., 1
Corbett, D., 685
Costall, B., 717, 785, 839
Couvaris, M. K., 461
Cox, A. J., 839
Cramer, C. P., 219
Crocker, A. D., 627
Crowe, S. F., 729

D'Agata, V., 53
Dajas, F., 439
Dalmaz, C., 439
Dar, M. Saeed, 747
Darmani, N. A., 95
Davies, B. T., 201
Debski, T. D., 11
DeHaven-Hudkins, D. L., 497
Depoortere, R., 311
De Vry, J., 769
Dias, M., 439
Dib, B., 649
Dickson, P. R., 387
Dilsaver, S. C., 213
Di Scala, G., 311
Doinikoff, M. S., 399
Domeney, A. M., 717, 839
Drago, F., 53
Durcan, M. J., 273

Edwardson, J. A., 597
Elliott, P. J., 329
Ellis, D. M., 167, 177
Elsmore, T. F., 117
Emerich, D. F., 149
Epstein, L. H., 11
Ericson, E., 843
Escalante, A., 83
Eterović, V. A., 445
Ettenberg, A., 465
Evans, E. B., 349

Fahey, J. M., 457
Feenstra, M. G. P., 539
Felicio, L. F., 571, 639
Ferchmin, P. A., 445
Ferkany, J. W., 497
Fernández-Guasti, A., 77, 83
File, S. E., 587
Fleetwood, S. W., 193
Flint Beal, M., 71
Fontana, D. J., 167, 177
Frambes, N. A., 371
Frankenhaeuser, M., 325, 697
Fredrikson, M., 697
Freeman, G. B., 259
Friedland, J., 831

Galanopoulou, P., 461
Galizio, M., 235
García, G. A., 477
Garcia-Cabrera, I., 577
Garner, L. L., 239
Genovese, R. F., 117
George, F. R., 795
Gessa, G. L., 253
Giannacopoulos, G., 461
Gibbs, J., 317
Gibbs, M. E., 729
Giordano, M., 135
Glaser, T., 769
Gleeson, S., 335
Glennon, R. A., 95, 557, 769, 835
Goldberg, S. R., 339
Gorzalka, B. B., 411, 825
Gosnell, B. A., 207
Grassi, M., 53
Graziani, M., 531
Greenberg, D., 317
Grilly, D. M., 643
Grota, L. J., 527

Haley, N. J., 17, 29
Halikas, J. A., 551
Hall, F. S., 277
Hamburger, R., 417
Harris, N., 359
Hartgraves, S. L., 267
Heinsbroek, R. P. W., 539
Heise, G. A., 155
Heishman, S. J., 561
Henningfield, J. E., 561
Hernandez, L., 227
Higgs, R. A., 835
Hilakivi-Clarke, L. A., 273
Hildebrand, J. P., 755
Hill, T. J., 167
Ho, I. K., 343, 773
Hoebel, B. G., 227
Hoh, J., 213
Hole, K., 505
Holtzman, S. G., 193
Hong, E., 83
Horger, B. A., 707
Horita, A., 375
Horvitz, J. C., 465
Hoskins, B., 773
Huang, C., 439
Hubbell, C. L., 633
Huestis, M. A., 561
Hughes, C. E., 693
Hui, Y., 633
Hull, E. M., 471
Humble, J. W., 17, 29
Hume, A. S., 343

Ieni, J. R., 259
Imura, H., 523
Iovino, M., 821
Isaacson, R. L., 457
Ishikawa, Y., 523
Ishizuka, Y., 773
Ito, Y., 343
Izquierdo, I., 439

Jacob, R. G., 11
Jacobson, K. A., 107
Jaeckle, R. S., 213
James, J. R., 59
Janak, P. H., 655
Jaspers, R. M. A., 1
Jenden, D. J., 799, 811
Johnson, D. N., 717
Journey, J. W., 235

Kaplita, P. V., 497
Karpiak, S. E., 679
Kawamura, H., 187
Keith, A. B., 597
Keller, E. A., 675
Kelley, A. E., 277
Kelly, M. E., 717, 785, 839
Kerenyi, S. Z., 267
Kerwin, J. M., 597
Kimchi, O., 417
Kisara, K., 779
Kishioka, S., 703
Kitabata, Y., 703
Klein, E., 417
Knusel, B., 799
Kofman, O., 417
Kolmonpunporn, M., 755
Komisaruk, B. R., 123
Kragh, R., 551
Krahn, D. D., 207

Lac, S. T., 551
Lacy, M., 89
Lasoń, W., 661
Lauretz, S. D., 799, 811
Lauria, N., 53
Lavoisy, J., 567
Lee, T. F., 107
Leeka, J. K., 379
Lehman, M. N., 755
Leibman, D., 161
Leibowitz, S. F., 735
Lemus, A. E., 477
Lenègre, A., 567
Lesko, L. J., 497
Leyton, M., 303
Li, D. J., 107
Lichtman, A. H., 219
Liebson, I. A., 511
Lindstedt, G., 325
Linnoila, M., 273
Lister, R. G., 273
Livezey, G. T., 761
Lloyd, S., 597
Lorden, J. F., 129
Lorens, S. A., 329, 689
Lu, S. Y., 135
Lucot, J. B., 283
Lundberg, U., 325, 697

McAllister, K. H., 101
McCabe, R. T., 365
McCarthy, M. M., 123
McCloskey, T. C., 177
McLamb, R. L., 41

Mahan, D. R., 365
Mabbutt, P. S., 587
MacDonall, J. S., 679
Macenski, M. J., 247
Maggi, A., 433
Majchrzak, M. J., 207
Maltchik, M., 47
Mareš, P., 667
Marglin, S. H., 425
Martin, B. R., 95
Martin, S. P., 493
Martinez, J. E., Jr., 655
Mattingly, B. A., 89
Mavunkel, B. J., 497
Medina, J. H., 439
Meisenberg, G., 689
Melchior, C. L., 205
Melin, B., 697
Melis, M. R., 253
Mercier, M., 607
Meyerson, L. R., 485
Michela, V. L., 129
Miguel, S., 567

Miller, S. H., 213
Mitsushio, H., 329
Miyamoto, Y., 703
Molina, V. A., 675
Moody, C. A., 755
Moralí, G., 477
Morita, N., 703
Morley, B. J., 239
Morrell, J., 383
Mortimer, R. B., 295
Moynihan, J. A., 527
Munson, H. R., 717
Murakami, Y., 523
Murphy, L. L., 299
Murphy, M. R., 267
Museo, E., 113
Musgrave, M. A., 387

Nanry, K. P., 41
Nasello, A. G., 571, 639
Naylor, R. J., 717, 785, 839
Nencini, P., 531
Netto, C. A., 47, 439
Newman, M., 417
Ng, K. T., 729
Nir, T., 417
Nocjar, C., 643
Norman, A. B., 135, 755
Nunes, M., 47

Oller Do Nascimento Curi, C. M., 399
Onaivi, E. S., 785
Oropeza, M. V., 477
Orsingher, O. A., 675
Ortiz, A., 679
Ozaki, M., 703

Pandey, U., 95
Panocka, I., 593
Paris, J. M., 329
Peck, J. A., 213
Pérez-Palacios, G., 477
Perkins, K. A., 11
Perry, E. K., 597
Picazo, O., 77
Porsolt, R. D., 567
Preston, K. L., 511
Prince, C. R., 613
Przewłocka, B., 661

Quillfeldt, J., 439

Ramzan, I., 583
Raskovsky, S., 439
Rehm, S. R., 17, 29
Reid, L. D., 425, 633
Ribeiro, E. B., 399
Rice, K. M., 799, 811
Riekkinen, P., 405
Riekkinen, P., Jr., 405
Roch, M., 799, 811
Rockhold, R. W., 773
Rokyta, R., 667
Rosecrans, J. A., 59
Rosenzweig, M. R., 295
Rosland, J. H., 505
Royal, S. A., 235
Russell, R. W., 811
Rzeszotarski, W. J., 497

Sadowski, B., 593
Sahgal, A., 597
Saitoh, Y., 187
Sakurada, S., 779
Sakurada, T., 779
Sanberg, P. R., 135, 755
Sandner, G., 311
Saunders, P. A., 343
Scaletta, L. L., 471
Scalzo, F. M., 371
Schechter, M. D., 623
Schefke, D. M., 167
Scheider, F., 439
Schenk, S., 707
Schnur, P., 383
Schulze, H. G., 411
Sexton, J. E., 11
Shelton, K., 707
Shimatsu, A., 523
Shimon, H., 417
Shipley, M. T., 135
Silveira, R., 439
Silverman, P. B., 231
Silverstein, E., 831
Simmons, W. H., 689
Sirviö, J., 405
Smith, E. O., 493
Smith, G. P., 317
Smith, J. D., 557
Smith, M. S., 299
Smith, R. B., 365
Smolen, A., 161
Smolen, T. N., 161
Soblosky, J. S., 259
Spadaro, F., 53
Sparber, S. B., 761
Spear, L. P., 371
Spencer, D. G., Jr., 769
Stancampiano, R., 253
Steardo, L., 821
Steger, R. W., 299
Stellar, J. R., 277
Steranka, L. R., 497
Stewart, J., 303
Stiller, R. L., 11
Stratton, S. E., 129
Suh, [illegible], 735
Sumová, A., 661
Svensson, T. H., 843

Tan-No, K., 779
Taylor, J., 359
Theophanopoulos, C., 461
Thompson, T., 247
Thurmond, J. B., 259
Tilson, H. A., 41
Toth, E., 587
Traumata, D., 213
Treit, D., 451
Tuomisto, M., 697
Turbek, J. A., 17, 29
Valenti, A., 433
Valerio, C., 53
van de Poll, N. E., 539
van Galen, H., 539
van Haaren, F., 539, 693
Vanacore, A., 821
Varonos, D., 461
Vécsi, L., 71
Velíšek, L., 667
Velíšková, J., 667
Villanueva, H. F., 59
Vogel, W. H., 359

Waite, J. J., 799
Wakade, C. G., 679
Wallin, L., 325
Walsh, T. J., 149
Walton, D. M., 63
Wamsley, J. K., 365
Wang, L. C. H., 107
Watson, N. V., 825
Weatherford, S. C., 317
Weiss, G. F., 735
Welker, J. A., 235
Wellman, P. J., 201
Welzl, H., 743
Wenger, G. R., 349
Williams, J. E. G., 289
Williams, L. R., 41
Wilson, W. A., 41
Wise, R. A., 113
Witkin, J. M., 117, 339
Witt, D. M., 63
Woolverton, W. L., 289
Wyatt, L. M., 755

Yabase, M., 375
Yamada, T., 779
Yamamoto, H., 703
Yamanishi, T., 703
Young, R., 717

Zaia, C. T. B. V., 399